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Introduction
Cilnidipine is reported to be a calcium channel blocker (CCB) that 
possesses clinical advantages over other dihydropyridine. It has 
less influence on heart rate and the autonomic nervous system 
than nifedipine Retard and causes less tachycardia than nisoldi-
pine in hypertensive patients [13,14]. Cilnidipine, was reported to 
cause an inhibition of  the pressor response induced by acute cold 
stress in addition to its hypotensive effect when administered to 
spontaneously hypertensive rats (SHRs)   [7].
However, no enough experimental studies have been carried out 
to investigate whether its possible protective effect to vital organs 
like kidneys in hypertension against stress could be related to pos-
sible antioxidant effects.
Antioxidant enzymes consist of  superoxide dismutase (SOD), 
catalase, and glutathione peroxidase. Dismutation of  oxygen free 
radicals by SOD produces hydrogen peroxide, a more stable reac-
tive oxygen species (ROS) which, in turn, is converted to water 
by catalase and glutathione peroxidase. An antioxidant effect may 
result from either activation or mimicry of  antioxidant defenses. 
Alternatively, it may be due to interaction with factors involved in 
the activation of  oxidative stress [20]. 
Historically, a study has reported that treatment of  the en-
dothelium with dihydropyridine calcium antagonists resulted in 
an increased release of  nitrogen monoxide that is not due to a 
modulation of  L-type calcium channels, because macrovascular 
endothelial cells do not express this channel. Also, The authors 
explained their findings via an increase in nitrogen monoxide 
availability that might cause part of  the vasodilation, and might 
contribute to the antithrombotic, antiproliferative, and antiathero-
sclerotic effects of  dihydropyridine calcium antagonists [1].
More recently, Dihydropyridine-based calcium antagonists 
(DHPs) are widely used drugs for the treatment of  hypertension 
and angina pectoris. Nifedipine, one of  the most widely used 
DHPs, inhibits apoptotic cell death of  endothelial cells (ECs) as 
well as vascular inflammation and subsequently improves endothe-
lial function in patients with cardiovascular risk factors, including 
hypertension and/or diabetes, thus slowing the development and 
Abstract
Aim:  Cilnidipine is a dihydropyridine calcium channel blocker (CCB) that blocks both L-type and N- type channels at the smooth 
muscle in the artery and calcium channels at the presynaptic nerve terminal, respectively. It is dihydropyridine calcium antagonist that 
possesses a slow-onset, long-lasting vasodilating effect.
The present study is designed to determine the effect of  cilnidipine on creatinine clearance, thiobarbituric acid reactive substance, as an 
index of  lipid peroxidation.  Additionally, the level of  superoxide dismutase enzyme in erythrocyte lysates and kidney catalase enzyme 
activitiy will be measured. Thirty-six albino  rats are divided into 3 separate groups: rats of  group  1 are control group,  rats of  group 
2 are administered by deoxycorticosterone acetate (DOCA) salt sc twice/week + 1% NaCl for 2 weeks to be rendered hypertensive) 
and  group 3 will receive 9 mg/kg cilnidipine for 3 weeks intragastrically after induction of  hypertension by DOCA-salt as group 2.
Results:  DOCA-injected albino rats show marked reduction in creatinine clearance. Treatment with cilnidipine improves creatinine 
clearance compared to the non-treated hypertensive group 2. Additionally, it reduces thiobarbituric acid reactive substance, as an index 
of  lipid peroxidation, with a significant increase in superoxide dismutase enzyme in erythrocyte lysates and kidney catalase enzyme 
activities.
Conclusion: This study points to the possible beneficial renal protective effects of  cilnidipine in hypertensive albino rats injected with 
DOCA for 2 weeks.
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progression of  atherosclerosis in these patients. Several papers 
have suggested that nifedipine exerts beneficial metabolic effects 
in vivo through its anti-inflammatory properties as well. However, 
the underlying molecular mechanisms for the cardiometabolic ac-
tions of  nifedipine remain to be elucidated, because ECs do not 
possess voltage-operated L-type calcium channels. Meanwhile, 
we have very recently found that Bay w 9798, a dihydropyridine 
structurally related to nifedipine with no calcium antagonistic 
ability, has anti-oxidative and anti-inflammatory properties in 
vitro. This means that more studies are needed to investigate the 
role of  oxidative stress in the development of  vascular injury, es-
pecially focusing on the relationships between advanced glycation 
end products-receptor system, oxidized low-density lipoprotein 
and tumor necrosis factor-alpha and vasculopathy. [23]
Amlodipine, being one of  the dihydropyridines, influence on the 
membrane permeability and cholesterol deposition in the mem-
brane, its antioxidative action, stimulation of  the NO release, as 
well extracellular matrix (ECM) regulation are not directly con-
nected to the decrease of  the resistance of  the blood vessels – an-
tihypertensive action. The cellular and molecular mechanisms of  
the observed amendment of  the endothelium function, delay of  
the cardiovascular action disturbances as the result of  amlodipine 
use are widely investigated, however up to now are not fully clear 
and unequivocal [22]. 
Therefore, the present study investigates, in the DOCA salt-in-
duced hypertension model, the effect of  treatment with cilnidi-
pine, as a dihydropyridine CCB, on creatinine clearance, and some 
oxidative markers, in kidney homogenates of  albino rats. 
Methods
Drugs
Cilnidipine was provided as powder by Lonsino Medical Products 
Co., Ltd. China.  Super oxide dismutase (RANSOD) was sup-
plied by Randox Laboratories, Kearneysville, WV, USA. All other 
chemicals were purchased from Sigma Chemicals, St Louis, MO, 
USA.
Animals
Thirty-six male albino rats weighing 180–200 g, were used in this 
study. They were randomly allocated into three groups of  12. Rats 
were housed in individual plastic cages and allowed one week to 
acclimate to their surroundings before the beginning of  the ex-
periments. Standard rat chow and tap water were available ad libi-
tum for the duration of  the experiments, unless otherwise noted.
Ethics
All procedures were in accordance with the National Institute of  
Health’s Guide for the Care and Use of  Laboratory Animals, as 
well as the guidelines of  the Animal Welfare Act.
Experimental protocol
Grouping and induction of  hypertension: Albino rats were di-
vided into three groups. Group 1 was the control group. Rats of  
group 2 were injected by Deoxycorticosterone acetate (DOCA) 
salt sc twice/week + 1% NaCl drunken for 2 weeks to be ren-
dered hypertensive (12). Rats of  group 3 were administered intra-
gastrically with 9 mg/kg/day cilnidipine, dissolved in a standard 
volume of  solution of  Arabic Gum [18,19] for 3 weeks intragas-
trically after induction of  hypertension by DOCA-salt as group 2.
To exclude any action of  solvent on high blood pressure and oth-
er parameters: In the pilot study, an experimental group (n = 12) 
received standard volume of  solution of  Arabic Gum equal to 
that used to dissolve cilnidipine in the experimental study to test 
it without the drug for a duration of  3 weeks ( duration of  drug 
therapy in group 3). Results were similar to that obtained with 
Group 2 (control hypertensive i.e. no change on the high blood 
pressure or anti-oxidant parameters→ same results as group 2 [ 
control hypertensive without treatment]). So no need to write an-
other column with the same results of  group 2 [ control hyper-
tensive with solvent]
Measurement of  systolic blood pressure (SBP) changes: 
SBP was measured by a tail-cuff  sphygmomanometer (UR-5000, 
Ueda Co, Ltd, Japan).  SBP measurements were conducted in all 
groups over a period of  8 hours post-injection at 30 min. inter-
vals.  For each animal an average of  at least three consecutive 
measurements was taken to reduce variability [3].
Renal function: Albino rats were individually housed in meta-
bolic cages for 24 hours at the end of  the study. During the 24 
hour period, animals continued to have free access to tap water 
and standard laboratory rat chow. Urine volume per 24 hours was 
calculated for each animal. Serum and urine creatinine concen-
trations were measured using a Beckman® Analyzer (Beckman 
Coulter, Brea, CA, USA) according to the picric acid colorimetric 
method,5 and creatinine clearance in different groups was calcu-
lated using the following formula: (urine creatinine(mg/dL) × 
urine volume per day(mL) ÷ 1440(min)) ÷ serum creatinine(mg/
dL)) ÷ body weight(g) × 100. (10).
Determination of  SOD enzyme level in erythrocyte lysates: 
At the end of  the study, blood samples were collected from rats 
from all groups for measurement of  SOD levels in erythrocyte 
lysates using commercially-available colorimetric assay kits, based 
on an indirect xanthine-xanthine oxidase method, [6] and results 
were expressed in IU/mL.
Measurement of  kidney thiobarbituric acid-reactive sub-
stances (TBARS) as a marker of  lipid peroxidation [4]: Kid-
ney homogenates were rinsed with cold 0.14 M sodium chloride 
and homogenized in 25% ice-cold 50 mM Tris-HCl buffer (pH 
7.4). 150 μL of  the tissue supernatant of  samples were diluted to 
500 μL with deionized water. 250 μL of  1.34% thiobarbituric acid 
was added to each tube, followed by the addition of  an equal vol-
ume of  40% trichloroacetic acid. The mixtures were then shaken 
and incubated for 30 minutes in a boiling water bath. Tubes were 
allowed to cool to room temperature, and the absorbance was 
then read at 532 nm, using zero concentration as blank.
Determination of  protein contents: The protein content of  
kidney homogenates was determined by spectrophotometer ac-
cording to the method of  [2]. The aim is to relate the oxidative 
marker concentrations to the total tissue protein.
Data analysis
The results are presented as mean ± standard deviation [SD], and 
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evaluated using one-way analysis of  variance (ANOVA), followed 
by Tukey's post hoc determination, using GraphPad Prism (ver-
sion 3.00; GraphPad Software, La Jolla, CA, USA).
Results
Effect of  cilnidipine treatment on systolic blood pressure 
(SBP) in rats exposed To  DOCA salt-induced hypertension
Figure 1 demonstrates a significant (**p < 0.05) decrease in SBP 
in DOCA salt-treated hypertensive rats treated with cilnidipine 
[ group 3]. Compared to the control group [1], the DOCA salt-
treated group (group 2) was associated with a significant (*p < 
0.05) increase in SBP.
Effect of  cilnidipine treatment on creatinine clearance in 
rats exposed to  DOCA salt-induced hypertension.
Figure 2 demonstrates an increase in creatinine clearance in 
DOCA salt-treated hypertensive rats treated with cilnidipine. Cre-
atinine clearance, in mL/min, of  the different groups (solution 
of  Arabic Gum, DOCA salt alone, and DOCA salt + cilnidipine) 
was calculated. Compared to the control group (1), the DOCA 
salt-treated group (2) was associated with a significant (*p < 0.05) 
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Figure (1).Reduction in high systolic blood pressure of   DOCA salt-induced hypertension  after intragastric administration 
of  cilnidipine in albino rats treated with DOCA-salt + 1% NaCl to induce hypertension.
Figure (1) A significant (p< 0.05) of   DOCA salt-induced hypertension  after intragastric administration of  cilnidipine in albino rats 
treated with DOCA-salt + 1% NaCl to induce hypertension.
Notes: *p < 0.05 significant increase in SBP compared to control non-hypertensive group. **p < 0.05 significant decrease in SBP in 
group (3) compared to DOCA-salt-treated group (2).
Abbreviation: SD = standard deviation.
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Figure (2): Improvement of  creatinine clearance after intragastric administration of  cilnidipine in albino rats treated with 
DOCA-salt + 1% NaCl to induce hypertension.
Figure (2) Improvement of  creatinine clearance after intragastric administration of  cilnidipine in albino rats treated with DOCA-salt + 
1% NaCl to induce hypertension.
Notes: *p < 0.05 significant reduction in creatinine clearance compared to control group. **p < 0.05 significant increase in creatinine 
clearance in group (3) compared to DOCA-salt + 1% NaCl to induce hypertension without cilnidipine treatment group (2).
Abbreviation: SD = standard deviation.
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decrease in creatinine clearance. This decrease was significantly 
(**p < 0.05) increased in cilnidipine group [3].
Effect of  cilnidipine treatment on TBARS and catalase 
enzyme activity in kidney homogenates in rats exposed to 
DOCA salt-induced hypertension
TBARS levels measured in tested kidney homogenates of  the 
cilnidipine-treated group [3] showed its significant (**p < 0.05) 
reduction compared to control normotensive and hypertensive 
levels in groups ( 2 & 3).
Meanwhile, catalase enzyme activity in the homogenates in cilnid-
pine-treated hypertensive albino rats was significantly (**p < 0.05) 
increased to almost the control levels of  the control normotensive 
group (1). However, group (2) hypertensive albino rats showed a 
significant (*p < 0.05) decrease in its activity compared to group 
normotensive (1) (Table 1).
Effect of  cilnidipine treatment on SOD levels in erythrocyte 
lysates  in rats exposed To  DOCA salt-induced hyperten-
sion
The mean ± SD of  cilnidipine on SOD levels in erythrocyte 
lysates.
Exposure to the DOCA salt-induced hypertension model showed 
a significant (*p < 0.05) decrease in SOD in erythrocyte lysates 
compared to control group. Concomitant administration of  
cilnidipine with DOCA salt significantly (**p < 0.05) increased 
SOD levels compared to control levels (Table 2).
Table (1). Effect of  cilnidipine on TBARS (in nmoL/mg tissue protein) and catalase enzyme activity (in μmoL/min/mg 
tissue protein) in kidney homogenates.The results are expressed as means ± standard deviation (n = 12 in each group). 
Superoxide dismutase enzyme Control group DOCA salt-only treated group DOCA salt+ cilnidipine
level of  SOD (IU/ml) in RBCs 
lysate
36.12± 4.8 12.25± 1.0* 92.62± 5.1**
Table (2).Effect of  cilnidipine on superoxide dismutase (SOD) level in IU/mL erythrocyte lysates isolated from tested 
albino rats in the three groups. The results are expressed as means ± standard deviation (SD) 
Discussion
The current study was undertaken to determine whether cilnidi-
pine administered to rats with DOCA salt-induced hypertension 
can protect against oxidative stress associated with hypertension, 
and can produce a beneficial effect on creatinine clearance com-
pared with rats without cilnidipine treatment.
The increase in TBARS production may contribute to impaired 
kidney function. Oxidative stress causes hypertrophy of  nephrons 
via increased production of  angiotensin II (AII), mediated by re-
active oxygen species (ROS) [16 and 8]. 
An increase in tubular endothelin-1 (ET-1) synthesis is reported 
in oxidative stress, it may induce fibroblast proliferation, intersti-
tial matrix deposition, and infiltration of  inflammatory cells that 
result in progressive tubulointerstitial fibrosis. Therefore, it seems 
that inhibition of  oxidative stress can significantly retard the pro-
gression of  renal and vascular complications. [17].
The antioxidant properties of  nifedipine, being one of  CCBs, 
are described as being due to either a direct scavenging effect or 
the preservation of  SOD activity. Under controlled experimental 
conditions, they may inhibit lipid peroxide formation at concen-
trations present in plasma. This antioxidant activity is found with 
high lipophilic CCBs when their chemical structure facilitates pro-
ton-donating and stabilization mechanisms that quench the free 
radical reaction [1].
Cilnidipine causes a decrease in aortic endothelin-1 (ET-1) gene 
expression might be related also to the protection by cilnidipine 
against the renal ischemic alterations caused by plasma renin ac-
tivity (PRA) elevation. Prevention of  PRA elevation by cilnidipine 
would suppress excessive AII production by renin of  kidney ori-
gin, thereby opposing AII-stimulated ET-1 gene overexpression 
in renal cells [18,19].
Experimental research has explained the mechanism of  DOCA 
salt-induced hypertension in the form of  induction of  renal oxi-
dative stress, as shown by a reduction in kidney glutathione, and 
an increase in lipid peroxidation [11,15].
Cilnidipine, an L/N-type calcium channel blocker (CCB), has 
been reported to have more beneficial effects on proteinuria 
progression in hypertensive patients than amlodipine, an L-type 
CCB. The N-type calcium channel blockade that inhibits renal 
sympathetic nerve activity might reduce glomerular hypertension 
by facilitating vasodilation of  the efferent arterioles. However, 
the precise mechanism of  the renoprotective effect of  cilnidi-
pine remains unknown. Because cilnidipine exerted significantly 
higher antioxidant activity than amlodipine in cultured human 
mesangial cells, we hypothesized that cilnidipine might exert a 
renoprotective effect by suppressing oxidative stress. Cilnidipine, 
but not amlodipine, ameliorated urinary albumin excretion and 
decreased urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 
liver-type fatty-acid-binding protein (L-FABP) in the hypertensive 
patients. Cilnidipine probably exerts a greater renoprotective ef-
fect through its antioxidative properties [21]
Calcium channel blockers (CCBs) are reported to regulate glo-
merular pressure by changing the afferent and efferent arteri-
Substance Control DOCA salt only-treated 
group
DOCA salt + cilnidipine
TBARS in nmoL/mg tissue protein 0.62 ± 0.1 12.56±  2.0* 0.28 ± 0.1**
Catalase enzyme activity in µmoL/
min/mg tissue protein
114.9±  9.6 1.47± 0.58* 86.43±  3.0**
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ole tone. ([24]) demonstrated that cilnidipine decreased single 
nephron filtration fraction, glomerular capillary pressure, affer-
ent and efferent arteriole resistance and proteinuria in nitric oxide 
synthase-inhibited SHR, indicating that cilnidipine attenuated the 
glomerular hypertension and prevented the proteinuria. Simi-
lar arteriole responses were observed in the kidney of  dogs [5] 
and hydronephrotic spontaneous hypertensive rats (SHR) ([9]). 
Vasodilatory effect of  cilnidipine, an L-type and N-type calcium 
channel blocker, on rat kidney glomerular arterioles. Int Heart 
J.,49:723–732 Importantly, [9] revealed that nifedipine, another 
L-type CCB, dilated afferent, but not efferent, artery, whereas 
cilnidipine dilated both afferent and efferent artery, suggesting 
that N-type calcium channel inhibition by cilnidipine might elicit 
efferent vasodilation. Therefore, it can be expected that the effect 
of  cilnidipine on glomerular hemodynamics explains part of  the 
renoprotective effect of  cilnidipine in SHR/ND in the present 
study. However,[5] reported that the effects of  cilnidipine and 
amlodipine on the efferent/afferent ratio arteriole dilation were 
similar in hydronephrotic kidney. Taken together, it seems likely 
that cilnidipine elicits renoprotective effect by regulating glomeru-
lar hemodynamics.
More animal studies are needed to be addressed to these issues 
and further in-vitro studies are needed to clarify the precise mech-
anisms by which the observed anti-oxidant and nephroprotective 
effects are elicited.
Conclusion
In conclusion, the tested dihydropyridine CCB cilnidipine could 
protect albino rats against the impairment of  kidney function 
evoked by hypertension induced by DOCA salt injection for 2 
weeks, and this may contribute to the beneficial effect against 
end-organ damage and oxidative stress reported in clinical trials. 
Further investigations on cilnidipine are needed to discover their 
beneficial role in protection or management of  renal diseases.
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